Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-center, Open-label, Study of Nilotinib at a Dose of 300mg Twice Daily in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

NCT00809211 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT00809211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00809211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-center, Open-label, Study of Nilotinib at a Dose of 300mg Twice Daily in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
February 29, 2016
Enrollment
40 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia